Coco Sumner es joven y guapa, desea ser una pop star y su apellido es el mismo que el de Sting porque de hecho es su hija. Y eso siempre ayuda.

Moderna says recently completed studies have found its vaccine to have a neutralizing effect against all COVID-19 variants tested, including the delta variant.; Credit: Fred Tanneau/AFP via Getty Images

Studies have found that Moderna's COVID-19 vaccine is effective against several variants of concern, including the delta variant, the biotech company announced.

Moderna said Tuesday that recently completed studies have found the vaccine to have a neutralizing effect against all COVID-19 variants tested, including the beta, delta, eta and kappa variants.

While still highly effective against the delta variant, the study showed the vaccine was less effective against it and certain other variants than against the original strain of the virus.

The antibody response against the delta variant was about two times weaker than against the ancestral strain of the virus.

The news echoes other findings that the Moderna and Pfizer vaccines are highly effective against the delta variant. A study published this month in Nature found that Pfizer's vaccine was able to neutralize variants including delta, though at somewhat reduced strength.

"These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants," Stéphane Bancel, Moderna's chief executive officer, said in a statement. "These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine."

The company also said it is developing a booster candidate: a 50-50 mix of its currently authorized COVID-19 vaccine and another messenger RNA vaccine it has developed.

The delta variant is spreading fast

The delta variant is the fast-moving form of the coronavirus that is now found in 96 countries, including the United States.

Last week, Dr. Anthony Fauci of the National Institutes of Health said the delta variant is "currently the greatest threat in the U.S. to our attempt to eliminate COVID-19," noting that the proportion of infections being caused by the variant is doubling every two weeks.

The delta variant is now infecting at least 1 out of every 5 people who get the virus in the United States. In some sections of the country, the variant is already far more common, particularly in parts of the Midwest and West. At its current pace, the delta variant is expected to be the dominant virus in the U.S. within weeks.

Dr. Maria Van Kerkhove, an infectious disease expert at the World Health Organization, called the delta variant "incredibly transmissible."

"These viruses are becoming more fit. The virus is evolving, and this is natural," she told NPR's Morning Edition. "It's more transmissible than the alpha variant, so we need to just do all we can to prevent as many infections as we can and do what we can do to reduce the spread."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Noubar Afeyan, cofounder and chair of Moderna Therapeutics and CEO of Flagship Pioneering, says that the breakthrough innovation behind the company’s Covid-19 vaccine came not as a stroke of luck, but from a repeatable process. He outlines a system called “emergent discovery” that involves working back from future ideals, pioneering in novel spaces, encouraging unreasonable ideas, and persistently questioning hypotheses. And he says this process applies to other industries besides life sciences. Afeyan is the coauthor, with HBS professor Gary Pisano, of the HBR article "What Evolution Can Teach Us About Innovation."

Moderna could seek government approval for its Covid-19 vaccine as early as November.

La ficción de época, que llegó a la sobremesa de La 1 en septiembre de 2023, tiene tres temporadas Leer

Title: Moderna Readies for Full Vaccine Approval, as Pfizer Submits Data on Booster Shot
Category: Health News
Created: 8/26/2021 12:00:00 AM
Last Editorial Review: 8/26/2021 12:00:00 AM

Berlin ; Boston : De Gruyter, [2023]

The pair hopes to stimulate the immune system to tackle tumors bearing mutant KRas proteins, one of cancer’s toughest targets

La inteligencia artificial (IA) promete transformar tanto el futuro del trabajo como la función de Recursos Humanos (RRHH). Alineado con esta premisa, IBM (NYSE: IBM) anunció hoy IBM Talent & Transformation, una nueva unidad destinada a ayudar a las organizaciones y a sus empleados a tener éxito en la era de la inteligencia artificial y la automatización.

Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.

Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year.

Moderna announces it has partnered with Lonza with the aim of producing one billion doses annually.

Moderna is finalizing the protocol for a phase 3 trial of its COVID-19 vaccine with a view to starting the study early in the summer. The establishment of the timeline, which follows FDA clearance to run a phase 2 trial, puts Moderna on track to win approval for its mRNA vaccine mRNA-1273 next year.

La crisis de refugiados venezolanos está a punto de superar la escala de la crisis siria. Para finales del 2019, 4 años después del comienzo de la crisis humanitaria venezolana, 4.6 millones de venezolanos han huido del país, alrededor del 16 por ciento de la población. La cifra es sumamente similar a los 4,8 millones…

Check out the companies making headlines in midday trading.

"We will all be supply constrained for quite some time, meaning we won't be able to make as many product as will be required to vaccinate everyone on the planet," CEO Stephane Bancel said on CNBC's "Squawk Box."

"This market does have a tendency to bounce between unbridled optimism and total despair — no middle ground," the "Mad Money" host said.

Moderna has received FDA approval for the company's Covid-19 vaccine to continue into the second phase. CNBC's Meg Tirrell reports.

The stocks making the biggest moves in premarket trading include Raytheon, ViacomCBS, Moderna, JetBlue, and more.

Moderna CEO Stephan Bancel tells "Squawk Box" that he anticipates the supply of Covid-19 vaccines will be 'constrained' at first and that the company will work closely with the U.S. government to distribute the first batches of the vaccine to areas that have the most need.

The FDA has approved Moderna's coronavirus vaccine candidate for a phase 2 trial, something the company calls a crucial step in its timeline. Moderna CEO Stephane Bancel joins "Squawk Box" to discuss.

ModernaThe biotech Moderna is developing experimental cancer vaccines.The leading coronavirus vaccine candidate just got up to $483 million in additional funding from the US government.The cash will pay for future trials to see if the vaccine works in humans, as well as for simultaneously ramping up production of the vaccine. "This allows us to go full speed and very aggressively," CEO Stephane Bancel told Business Insider in a Thursday video interview, saying the vaccine program will now go "as fast as humanly possible."The upstart biotech Moderna developed the vaccine candidate in record time using its technology platform called messenger RNA. The new technology has yet to produce an approved vaccine, but has shown promise in its potential to quickly respond to new viruses. The first human

The drug developer had previously said it expected mid-stage trials to begin in the current quarter, with the aim to start late-stage studies in the fall.

Online Resource

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

Gilead has a head start on an antiviral, while Moderna is pursuing a novel mRNA vaccine

Gilead toma ventaja gracias a un antiviral, mientras que Moderna está buscando una nueva vacuna ARNm.

Program boosts effort by the mRNA therapy pioneer to be first with a coronavirus vaccine

Program boosts effort by the mRNA therapy pioneer to be first with a coronavirus vaccine

The pair hopes to stimulate the immune system to tackle tumors bearing mutant KRas proteins, one of cancer’s toughest targets